Bio-Techne (TECH) Competitors

Neurocrine Biosciences (NASDAQ:NBIX) and Bio-Techne (NASDAQ:TECH) are both large-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their community ranking, analyst recommendations, valuation, dividends, media sentiment, risk, profitability, earnings and institutional ownership.

Does the media favor NBIX or TECH?

In the previous week, Bio-Techne had 1 more articles in the media than Neurocrine Biosciences. MarketBeat recorded 13 mentions for Bio-Techne and 12 mentions for Neurocrine Biosciences. Neurocrine Biosciences' average media sentiment score of 1.74 beat Bio-Techne's score of 0.87 indicating that Neurocrine Biosciences is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Neurocrine Biosciences	12 Very Positive mention(s)	0 Positive mention(s)	0 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Bio-Techne	6 Very Positive mention(s)	1 Positive mention(s)	6 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Does the MarketBeat Community prefer NBIX or TECH?

Neurocrine Biosciences received 616 more outperform votes than Bio-Techne when rated by MarketBeat users. Likewise, 77.39% of users gave Neurocrine Biosciences an outperform vote while only 62.64% of users gave Bio-Techne an outperform vote.

Company	Underperform	Outperform
Neurocrine Biosciences	Outperform Votes 1010 77.39%	Underperform Votes 295 22.61%
Bio-Techne	Outperform Votes 394 62.64%	Underperform Votes 235 37.36%

Which has more risk & volatility, NBIX or TECH?

Neurocrine Biosciences has a beta of 0.35, meaning that its share price is 65% less volatile than the S&P 500. Comparatively, Bio-Techne has a beta of 1.28, meaning that its share price is 28% more volatile than the S&P 500.

Is NBIX or TECH more profitable?

Neurocrine Biosciences has a net margin of 17.21% compared to Bio-Techne's net margin of 12.86%. Neurocrine Biosciences' return on equity of 15.68% beat Bio-Techne's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Neurocrine Biosciences	17.21%	15.68%	11.38%
Bio-Techne	12.86%	12.76%	9.59%

Do analysts recommend NBIX or TECH?

Neurocrine Biosciences presently has a consensus target price of $163.91, indicating a potential upside of 30.45%. Bio-Techne has a consensus target price of $81.78, indicating a potential upside of 14.73%. Given Neurocrine Biosciences' stronger consensus rating and higher probable upside, equities research analysts clearly believe Neurocrine Biosciences is more favorable than Bio-Techne.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Neurocrine Biosciences	0 Sell rating(s)	5 Hold rating(s)	18 Buy rating(s)	1 Strong Buy rating(s)	2.83
Bio-Techne	0 Sell rating(s)	3 Hold rating(s)	6 Buy rating(s)	0 Strong Buy rating(s)	2.67

Which has stronger valuation & earnings, NBIX or TECH?

Neurocrine Biosciences has higher revenue and earnings than Bio-Techne. Neurocrine Biosciences is trading at a lower price-to-earnings ratio than Bio-Techne, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Neurocrine Biosciences	$1.89B	6.74	$249.70M	$3.73	33.69
Bio-Techne	$1.17B	9.67	$168.10M	$0.94	75.83

Do institutionals & insiders hold more shares of NBIX or TECH?

92.6% of Neurocrine Biosciences shares are held by institutional investors. Comparatively, 98.9% of Bio-Techne shares are held by institutional investors. 4.3% of Neurocrine Biosciences shares are held by company insiders. Comparatively, 3.9% of Bio-Techne shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Neurocrine Biosciences beats Bio-Techne on 14 of the 19 factors compared between the two stocks.